Z

Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702

Watchlist Manager
Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
Watchlist
Price: 16.9 CNY -2.99% Market Closed
Market Cap: 5.9B CNY
Have any thoughts about
Zhejiang Tianyu Pharmaceutical Co Ltd?
Write Note

Zhejiang Tianyu Pharmaceutical Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zhejiang Tianyu Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
Cost of Revenue
-ÂĄ1.7B
CAGR 3-Years
-3%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cost of Revenue
-ÂĄ1B
CAGR 3-Years
-9%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cost of Revenue
-ÂĄ6.1B
CAGR 3-Years
-17%
CAGR 5-Years
-14%
CAGR 10-Years
-24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cost of Revenue
-ÂĄ3.9B
CAGR 3-Years
0%
CAGR 5-Years
-5%
CAGR 10-Years
-11%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cost of Revenue
-ÂĄ28.8B
CAGR 3-Years
-2%
CAGR 5-Years
-7%
CAGR 10-Years
-9%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cost of Revenue
-ÂĄ242.3m
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Tianyu Pharmaceutical Co Ltd
Glance View

Market Cap
5.8B CNY
Industry
Pharmaceuticals

Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical raw materials and intermediates. The company is headquartered in Taizhou, Zhejiang and currently employs 4,991 full-time employees. The company went IPO on 2017-09-19. The firm operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high blood pressure drug intermediates, anti-asthma drug intermediates and antiviral drug intermediates. The firm also operates Other segment. The firm sells its products to both domestic and international markets, including Europe, the United States, Japan, South Korea and so on.

Intrinsic Value
20.88 CNY
Undervaluation 19%
Intrinsic Value
Price
Z

See Also

What is Zhejiang Tianyu Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-1.7B CNY

Based on the financial report for Sep 30, 2024, Zhejiang Tianyu Pharmaceutical Co Ltd's Cost of Revenue amounts to -1.7B CNY.

What is Zhejiang Tianyu Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-12%

Over the last year, the Cost of Revenue growth was -6%. The average annual Cost of Revenue growth rates for Zhejiang Tianyu Pharmaceutical Co Ltd have been -3% over the past three years , -12% over the past five years .

Back to Top